most of them the study population does not reach 200 cases. Interestingly, studies with larger cohorts give results similar to ours. In a study of 197 patients (163 Caucasians and 34 blacks) Chen et al 5 found a higher prevalence of the double null GSTT1 and GSTM1 genotype among black children. In a large series of 651 (616 Caucasians and 35 black) ALL patients Davies et al 8 found GSTT1 and GSTM1 gene frequencies similar to those of controls, but they do not confirm the data on black children. In contrast a Canadian study on 177 cases showed an increased frequency of GSTM1 null genotype in children with ALL. 9 A smaller number of studies have been reported on the possible influence of GSTP1 genotype on childhood ALL. All of them had negative results; only one on 278 cases reported a role of GSTP1 in the susceptibility to childhood ALL in individuals carrying the variants Val105/Ala114 but did not shown clear results on the role of each variant. 10 In these studies, positive results were obtained in a French-Canadian population, suggesting that the influence of GSTs on the risk of leukemia could differ among populations, or a different exposure could be involved in leukemogenesis.
Several factors must be considered in the design of a reliable case-control study. A large sample size with an adequate power is one of the most important factors. The choice of the control population is also crucial because the possible different exposure to environmental toxicants should be considered. All these factors were taken in account in our study and, in order to rule out geographical differences in genetic backgrounds and in environmental exposure to carcinogens, the normal controls were matched not only for gender and age, but also for geographical area of residence. This is the first study that takes into consideration also the residence area as a criterion for the selection of controls.
In addition this is the second study after that of Davies et al 8 that considered the possible influence of genotype on the patients' clinical characteristics, confirming the lack of association between ALL subtype and GST polymorphism.
In conclusion, this study represents one of the largest studies on GSTT1 and GSTM1 genotypes, and the largest study on GSTP1 genotypes in children with ALL. Our data do not support a role of GST genotypes in genetic susceptibility to ALL. Our findings, although negative, contribute to give a definitive answer to the question on the role of GST genotype in childhood ALL etiology at least in the Caucasian population.
Expression and mutation status of candidate kinases in multiple myeloma Leukemia (2007) Kinase hyperactivity often results in deregulation of cellular pathways involved in proliferation and survival. In multiple myeloma (MM), for example, the translocation of FGFR3, a receptor tyrosine kinase (RTK), to the immunoglobulin heavy chain locus is found in 15% of patients. FGFR3 mutations, activating the receptor, are found in both primary patient samples and cell lines, supporting the role of FGFR3 signaling in the pathogenesis of the disease. In recent years, several other kinases have also been reported to be somatically mutated in hematologic and solid organ malignancy. Furthermore, mutated kinases are ideal targets for therapeutics. These observations have led us (and others) to attempt kinome-wide sequencing in the hope of identifying other, as yet unidentified, somatic mutations in MM by focusing on RTKs. Of note, major sequencing efforts are currently being launched that may in part be duplicative. Subsequently, we report here our data to date derived from the sequencing of the kinase domains of 31 candidate genes and one kinase-regulatory gene CKS1B. Although we did not find recurrent mutation in genes other than FGFR3, we have noted non-synonymous sequence differences in ROR2, EGFR, GUCY2F and EPHB4 that are not present in dbSNP or pooled DNA from ethnically diverse populations that may now be further studied in larger cohorts of MM patients for any pharmacogenetic significance.
Our general approach is detailed in Figure 1 . Genomic DNA from 32 MM cell lines, and from CD138 þ purified bone marrow plasma cells from 24 MM patients (including 12 hyperdiploid), eight monoclonal gammopathy of undetermined significance (MGUS) and five plasma cell leukemia (total of 37 samples) were used in the study. Patient samples were obtained from Mayo Clinic (Scottsdale, AR, USA) and Princess Margaret Hospital (Toronto, ON, Canada) after informed consent. When necessary, a whole genome amplification method (GenomiPhi, GE Health Care, Piscata-way, NJ, USA Pharmacia) was used to amplify a limited amount of patients' genomic DNA.
PCR amplification of genomic DNA was performed in 96-well plates using primers that have been previously described 1,2 or which were designed using the Primer3 program through the Canadian Bioinformatics Resource web portal (cbr-rbc.nrccnrc.gc.ca/index_e.php). Aliquots of PCR products were sequenced on 96-well plates without purification using nested sequencing primers. Sequence files generated from ABI 3730XL DNA analyzer were analyzed using SeqScape software (Applied Biosystems, Foster City, CA, USA) (ABI) and sequence changes were visually and manually inspected. Mutations were confirmed by reverse direction and repeat sequencing. In 17 of the genes sequenced, we covered 100% of the kinase domain whereas 15 of these kinases had their kinase regions partially sequenced between 55 and 85%. JAK2 was only sequenced within the mutation hot spot observed in lymphoproliferative disorders whereas CSK1B was fully sequenced.
Initially, we focused on 24 RTKs (Figure 2a ) implicated in other malignancies and one kinase regulatory subunit (CKS1B) that is often amplified in MM.
In an attempt to narrow the search, we then employed gene expression profile data to look for other promising kinase candidates to screen for somatic mutations. From a reference list of 518 kinases in the human genome, we identified 1098 probe IDs on Affymetrix U133 Plus 2 corresponding to known kinases. Analysis of these kinases in healthy controls, MGUS, smouldering MM (SMM), MM and MM cell lines revealed significant differential expression in 185 unique kinases (Supplementary Information). Supervised hierarchical clustering indicated by the heatmap in Figure 2b grouped the normals, cell lines and patient samples as separate clusters. When normal plasma cells were compared with the malignant counterparts of MGUS, SMM or MM, 64% (65/102) of kinases showed at least 2.84-fold higher expression in the disease state whereas 36% of the kinases (37/ 102) showed diminished expression. From this list of upregulated RTKs, seven RTKs were identified for sequencing: JAK3, MET, KIT, CSK, ABL1, FGFR3 and ROR2.
ROR2 expression showed a pattern reminiscent of the gene 'spikes' observed in translocated FGFR3, albeit at a level 10-fold less than FGFR3 (Figure 3) . Like FGFR3 mutations, ROR2 allelic mutations cause skeletal malformations in that inactivating mutations result in autosomal dominant brachydactyly type B 3 and autosomal recessive Robinow syndrome. 4 ROR2 is a negative regulator of Wnt signaling 5 and its expression is linked in patients to the absence of bone disease (not shown). The parallel skeletal phenotype of germline mutations in both FGFR3 and ROR2, together with the spiked and differential pattern of gene expression noted above, led us to consider ROR2 as strong candidate for kinase mutation screening.
As a positive control, sequencing of the FGFR3 kinase domain of MM cell lines confirmed the known K650E FGFR3 mutation in OPM1 and OPM2 (Figure 2c) . Interestingly, however, we also identified a novel heterozygous non-synonymous mutation S433C (AAG to GAG) in KMS12PE, a cell line derived from pleural effusion of an MM patient (Figure 2c ). This mutation is not present in the bone marrow-derived cell line from the same patient, KMS12BM (Figure 2c ), suggesting that this mutation appeared later during disease progression. Sequencing of this exon in 37 patient samples did not identify additional mutations in this codon or in this region. However, in the same set of patient samples, we identified a novel mutation in an MGUS patient that was not seen in peripheral blood control lymphocytes from the same individual. This heterozygous non-synonymous mutation, GCC to AGC (G197S), located in the immunoglobulin 2 domain, has not been previously reported. More importantly, this mutation is the first evidence that FGFR3 point mutation can occur early in the development of MM.
Our broader kinome sequencing effort generated B2.0 megabases of sequence. Analysis of the sequences generated identified several single nucleotide polymorphisms (SNP) (Supplementary Information) located in the coding exons of the sequenced genes including sequence differences that have not been reported or cataloged as SNP, perhaps owing to rarity of these alleles in the general population. Alternatively, these may represent rare sequence alterations in MM. We also identified four genes ROR2, EGFR, GUCY2F and EPHB4 that showed single nucleotide change (Figure 2c ) when compared to their known coding sequence that were more suggestive of acquired mutation.
EGFR, GUCY2F and EPHB4 each showed single nucleotide changes (Supplementary Table) in at least one sample when compared to their known coding sequence, but the significance of these codon differences is undetermined. For example, a G917R change in EGFR sequenced from cell line MM1 was not seen in dbSNP or in ethnic pool DNA, but Western and fluorescence activated cell sorting analyses (not shown) showed no expression of the EGFR in this cell line, indicating that the consequence of this amino-acid change is neither functionally nor physiologically relevant. Similarly, single nucleotide differ- 
Figure 1
The general schema and workflow are schematically illustrated.
Letters to the Editor ences were detected in GUCY2F (L100V) from the L363 cell line and EPHB4 gene (R564K) from the KMS26 cell line, but the unavailability of control DNA from these cell lines made it impossible to determine the exact nature of these observations. The functional importance of these changes can only be inferred from amino-acid alignment of homologous sequences in other organisms. Generally, Leu at amino-acid position 100 in GUCY2F (L100V) is conserved in most species, but it is substituted for Phe in Bos taurus and Val in Oryzias latipes, suggesting that an amino-acid change in this position may not be critical to the function of this protein. Conversely, Arg at position 564 in EPHB4 appears to be highly conserved in EPHB gene family of human and other species (data not shown). Analysis of these sequence differences in 24 MM, eight MGUS and five plasma cell leukaemia patient samples did not show similar changes in EGFR, GUCY2F or EPHB4 genes.
Two non-synonymous variations were observed in ROR2: G695R located in the kinase domain (in two cell lines) and H349D (in cell line MM1) mapped to the kringle domain. No similar sequence changes were observed in 428 chromosomes of various ethnicity or reported in dbSNP; however, control genomic DNA was not available from the affected individuals to confirm mutation. For H349D, it is not known whether the resulting amino-acid change from basic to acidic is critical to the function of the protein, but His in this region can also be substituted for Asp in the kringle domain 3 of hepatocyte growth factor and Caenorhabditis elegans CAM-1, 4 suggesting that the amino acid His in this position may not be a critical amino acid.
Our study is the first reported attempt at high-throughput screening for kinase mutations in MM. With the exception of FGFR3, the sequence differences detected involved single nucleotide changes in no more than two (and usually one) of the 32 cell lines and 37 MM individuals sequenced. Of note, our methodology would not detect big deletions that span the exons being studied. Nevertheless, our data suggest that within the 31 sequenced kinases, none is commonly mutated and activated in MM with the exception of FGFR3. However, as we focused our study mainly on the kinase domain of selected tyrosine kinases, screening the full coding regions of other kinases may yet uncover a common mutation with functional significance. Large-scale sequencing efforts are about to begin and can be informed by these preliminary results.
The gene ROR2 exhibits differential expression between myeloma patients and normal counterparts, is associated with hereditary skeletal defects similar to the myeloma-associated FGFR3, is associated with less bone disease in patients and contains point mutations not present in GenBank. The role of ROR2 thus deserves further analysis.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) 
